Sun Pharma strikes a global deal with Philogen for cancer immunotherapy, Fibromun; shares dip 

The collaboration, disclosed on October 1, 2024, grants Sun Pharma the worldwide rights to market Fibromun, which is in the final stages of clinical trials for treating soft tissue sarcoma and glioblastoma